SpaceX Stock Decline: Post-IPO Price Fall Tests Investor Confidence and Recovery Prospects

SpaceX shares plummeted 45% from peak, falling below the $135 IPO price just weeks after the largest offering in history.

SpaceX shares plummeted 45% from peak, falling below the $135 IPO price just weeks after the largest offering in history.

Xanthine oxidase produces uric acid through purine breakdown, and its dysregulation drives gout and hyperuricemia in millions of patients globally.

INDB's $81.8M Q2 earnings and $200M buyback reflect steady fundamentals, but growth headwinds and margin pressure demand scrutiny before buying.
Tesla shares closed at $380.84 on July 17 after a 2.6% weekly decline, breaking key support ahead of July 22 earnings.

Xanthine oxidase catalyzes uric acid production in the body, driving a $5+ billion pharmaceutical market focused on preventing and treating gout-related joint damage.

First Horizon beat Q2 earnings estimates but fell 3.85%, revealing investor concerns about margin compression despite profit growth.

Bloom Energy faces a 1,000% rally and delivery risk: can the company execute $3.8B revenue guidance and double production capacity?

A single enzyme controls uric acid production—and why some gout drugs work better than others.

Three tech stocks—Nvidia, Alphabet, and Micron—lead the 2026 AI boom, each occupying a distinct position in the infrastructure powering artificial intelligence.

How the enzyme that produces uric acid shapes gout risk, kidney damage, and emerging pharma investments.